Bitter pills

1. At a Glance

• Bitter pills: a The Hindu editorial (1 Oct 2026) backing the Supreme Court's criticism of the gap between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of some drugs, including cancer drugs. In some cases the gap is up to 1,000% [1].
• How it works: hospitals decide which brand a patient gets. Drug companies therefore set inflated MRPs with low PTRs, and the hospital keeps the difference. The editorial calls this a kickback "economically" though not "technically" [1].
• The practice exists because of a regulatory gap in the Drugs (Prices Control) Order (DPCO), 2013 [1]. That Order is the main instrument for regulating drug prices in India [3].
• UPSC relevance: health financing, affordability of medicines, competition law, the reach of regulation, and judicial intervention in economic policy (GS-II and GS-III).

2. Why in the News

• Sept–Oct 2026: The Supreme Court criticised PTR–MRP gaps of up to 1,000% for some drugs, including cancer drugs [1].
• Competition Commission investigations have found that private hospitals force patients to buy from on-premise pharmacies. This stops patients from shopping around [1].
• Drug regulators in Karnataka and Maharashtra have also flagged the financial strain on patients [1].
• Aug 2026: The Government is reported to be considering adding Trade Margin Rationalisation (TMR) to the DPCO [7].

3. Background & Evolution

• DPCO, 2013: Drug prices in India are regulated under this Order [3]. Under it, the National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for drugs listed in Schedule-I [4].
• 26 Feb 2019: The NPPA used its extraordinary powers in public interest under Para 19 of DPCO 2013 to bring 42 non-scheduled anti-cancer drugs under price control through TMR [2][5].
• Under this TMR, the trade margin was capped at up to 30% of the price. Prices of 526 brands fell by an average of about 50%, with some reductions of up to 90% of MRP. Estimated annual savings for patients were about ₹984 crore [2][5].
• Parliamentary Committee ("Price Rise of Medicines in the Pharmaceutical Sector"):
• Found that drug price increases have broadly tracked inflation, but trade margins stay high for some medicines [6].
• Said TMR is a viable way to control prices [6].

• Noted that DPCO 2013 allows margin capping only for a limited period, and recommended amending the DPCO to give TMR a permanent legal basis [6].

• 2026: The Government is weighing that amendment [7].

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• Principal–agent failure: hospitals choose the brand, so companies compete for hospitals rather than patients [1].
• Adverse selection against cheaper drugs: lower-priced equivalent drugs lose out because they earn hospitals less [1].
• Capping margins works. The 2019 TMR cut prices by about 50% on average [2].

Social / Health

• Patients with cancer and chronic diseases face heavy costs. High prices can make them skip or stop long treatment regimens [1].
• Catastrophic health spending hits patients who are captive to hospital pharmacies hardest [1].

Legal / Regulatory

• The regulatory gap is in DPCO 2013 [1]. TMR has only a temporary legal footing under it [6].
• The Supreme Court stepped in because the regulator had not closed this gap [1].
• The Competition Commission of India (CCI) has found that hospitals force patients to buy in-house, which is an abuse of their captive position [1].

Ethical / Governance

• The practice is legal in form but works like a kickback in substance. This raises issues of medical ethics and hospital accountability [1].
• State drug regulators (Karnataka, Maharashtra) have raised concerns. This shows that Union and State bodies need to coordinate on enforcement [1].

Administrative

• Options include:
• making TMR permanent inside the DPCO [6][7];
• requiring PTR to be disclosed;
• letting patients buy outside the hospital pharmacy.

6. Recent Developments (last 12-18 months)

• Aug 2026: The Government is considering adding trade margin rationalisation to the DPCO [7].
• Sept 2026: The Supreme Court criticised PTR–MRP gaps of up to 1,000% for drugs including cancer drugs [1].
• 1 Oct 2026: The Hindu editorial "Bitter pills" welcomed the Court's intervention [1].
• Karnataka and Maharashtra drug regulators have flagged the financial burden on patients [1].

7. Prelims Hooks

• Drug prices in India are regulated under the Drugs (Prices Control) Order, 2013 [3].
• The NPPA fixes ceiling prices for drugs in Schedule-I of DPCO 2013 [4].
• Para 19 of DPCO 2013 gives extraordinary powers "in public interest" to control prices of non-scheduled drugs [2].
• TMR was applied to 42 non-scheduled anti-cancer drugs in 2019 [2].
• The NPPA meeting that invoked Para 19 for cancer drugs was held on 26 Feb 2019 [2].
• The trade margin on these 42 drugs was capped at up to 30% [2].
• The 2019 TMR covered 526 brands. The average price cut was about 50%, and some prices fell by up to 90% [2][5].
• Estimated annual savings to patients were about ₹984 crore [2].
• The Supreme Court flagged PTR–MRP gaps of up to 1,000% [1].
• The CCI has found that private hospitals force patients to use in-house pharmacies [1].
• DPCO 2013 allows trade margin capping only for a limited period [6].

8. Why a Price Ceiling Cannot See the Hospital's Profit

• The law caps the price the patient pays, not the profit in the middle
• The NPPA's tools work on the MRP, the price printed on the pack [4].
• The hospital's profit comes from the gap between the PTR and the MRP. No rule in DPCO 2013 limits that gap in normal times [1][6].

• So a company can keep the MRP legal and still make it high enough to give the hospital a large margin.

• Most drugs are not under a ceiling at all

• Only drugs in Schedule-I get a ceiling price [4].
• For non-scheduled drugs, the NPPA does not fix the launch price. It only limits the price rise to 10% a year [8].

• So a company can launch a new brand with a very high MRP. After that, the 10% rule protects that high starting price instead of lowering it.

• The regulator cannot even see the numbers

• PTS (Price to Stockist, the price at which a company sells to the wholesaler) is not made public [8].
• Nobody can prove a 1,000% gap without data that shows both ends of the chain.

• This is why the Parliamentary Committee asked for studies that compare PTS with MRP [8].

• Price control on paper did not stop prices rising

• Stents have been under price control since 2017. Even so, the Committee found that bare-metal stent prices rose 44% and drug-eluting stent prices rose 29% between 2017 and 2024 [8].
• A ceiling limits how high a price can go. It does not stop prices climbing up to that ceiling.

9. Why a Proven Fix Still Rests on Emergency Powers

• The 2019 success used a power meant for emergencies
• The cancer-drug margin cap used Para 19, the NPPA's extraordinary power "in public interest" [2].

• An emergency power is used case by case. It is not a standing rule that covers all drugs.

• The law allows a margin cap only for a limited period [6][8]

• Each cap can lapse or be challenged. Companies know the cap is temporary, so they have little reason to change how they price.

• Parliament has already asked for a permanent rule

• The Standing Committee on Chemicals and Fertilisers (report dated 1 Dec 2025) asked the government to amend DPCO 2013 so that TMR gets a permanent legal basis [8].
• It also asked the NPPA to bring non-scheduled drugs and FDCs (fixed-dose combinations, two or more medicines in one pill) under price control [8].

• Ten months later, in Aug 2026, the government was still only "weighing" the change [7].

• When the executive delays, the courts fill the gap

• The Supreme Court criticised the practice in Sept 2026, after Parliament's committee had already recommended a fix [1][8].
• This is a good exam example: the judiciary acting on an economic issue because the executive had not closed a known gap.

10. Fines on Paper, Little Money Collected

• A cap works only if breaking it costs the company something
• Between 1997 and Jan 2011, the NPPA issued demand notices (orders to pay back the extra amount charged) in 786 cases. The total overcharge was ₹2,328.53 crore [9].

• Only ₹207.86 crore was recovered, including money recovered through courts. That is less than one rupee in ten [9].

• Why recovery fails

• Companies challenge the notices in court. The money stays with them while the case goes on.

• So overcharging can pay even after a company is caught.

• What this means for any new TMR rule

• A permanent margin cap will fail in the same way unless the NPPA can collect quickly.
• Karnataka and Maharashtra regulators have raised the problem [1]. State drug controllers can check hospital pharmacies on the spot. The NPPA in Delhi cannot.

11. The Industry's Best Argument, and Why It Falls Short

• The strongest objection
• Trade margins pay wholesalers, stockists and chemists. They carry medicines to small towns and store cold-chain drugs such as many cancer medicines.
• Industry fears that a tight cap on every drug could make low-margin brands unprofitable. Firms might then stop selling them, and patients would lose access.

• This worry is real and should not be dismissed.

• Why it does not fit this case

• The problem here is not a normal distribution margin. It is a gap of up to 1,000% that goes to the hospital, which picks the brand [1].
• The 2019 cap still allowed a 30% margin. Prices of 526 brands fell by about half, and patients saved about ₹984 crore a year [2][5].

• A 30% margin still pays for distribution. A 1,000% margin pays for a hospital's choice of brand.

• What to concede

• One flat margin for all drugs could hurt medicines that are costly to store or move. A tiered cap, with different margins for different types of drugs, answers this better than a single number.
• Any permanent TMR should be paired with checks on whether drugs are still available after prices fall.

12. Who Should Do What Next

• Ministry of Chemicals and Fertilisers: make TMR permanent

• Amend DPCO 2013 as the Standing Committee recommended, so that margin caps no longer depend on Para 19 [8].

• NPPA: publish the price chain

• Carry out and publish the PTS versus MRP studies the Committee asked for [8].

• Once the gap is public, patients, the CCI and courts can all act on it.

• NPPA: control launch prices, not only yearly rises

• The Committee asked for price control on non-scheduled drugs and FDCs, where the 10% yearly cap does nothing about a high launch price [8].

• CCI and State regulators: open up the hospital pharmacy

• CCI has found that patients are forced to buy from in-house pharmacies [1].

• Patients need a real right to buy the same drug outside. Otherwise a margin cap only moves the hospital's profit somewhere else.

• Use the ceiling-price tool where it works

• Fixing prices under NLEM 2022 (National List of Essential Medicines) saved patients about ₹3,788 crore a year [10].
• Adding more cancer and chronic-disease drugs to the NLEM brings them under a hard ceiling. That removes much of the room for inflated MRPs.

13. Anchors for Answers

• Data: PTR–MRP gap of up to 1,000% on some drugs, including cancer drugs, flagged by the Supreme Court [1]
• Data: 2019 TMR on 42 cancer drugs: 526 brands, prices down about 50%, savings about ₹984 crore a year [2][5]
• Data: NPPA recovered only ₹207.86 crore of ₹2,328.53 crore overcharged (1997–Jan 2011) [9]
• Data: NLEM 2022 price fixation saved patients about ₹3,788 crore a year [10]
• Data: Stent prices rose 44% (bare-metal) and 29% (drug-eluting) in 2017–2024 despite price control [8]
• Report/Committee: Standing Committee on Chemicals and Fertilisers, "Price Rise of Medicines in the Pharmaceutical Sector" (1 Dec 2025): make TMR permanent, disclose PTS vs MRP, control non-scheduled drugs and FDCs [8]
• Law/Case: DPCO 2013, Para 19 (extraordinary powers in public interest) [2]; Supreme Court criticism of PTR–MRP gaps (Sept 2026) [1]
• Scheme: NLEM-based ceiling prices under Schedule-I: a hard cap that leaves little room for inflated MRPs [4][10]

14. Mains Relevance

• GS-II: Issues relating to the development and management of Health; government policies and interventions; role of the judiciary.
• GS-III: Inclusive growth; Competition and regulation (the CCI); market failures.
• GS-IV: Ethics in the medical profession; conflict of interest.
• Possible question stems: 1. "Price regulation of medicines in India addresses ceiling prices but not the trade margins that distort hospital procurement." Critically examine this statement in the context of DPCO 2013. 2. Discuss Trade Margin Rationalisation as a tool for making medicines affordable. Should it be given a permanent statutory basis? 3. "Captive hospital pharmacies turn patients into price-takers." Examine the role of competition law and judicial oversight in correcting this.

15. Related Topics to Study Next

• National List of Essential Medicines (NLEM): the basis for Schedule-I of the DPCO.
• Essential Commodities Act, 1955: the parent statute under which the DPCO is issued.
• Competition Act, 2002 and the CCI: abuse of dominance by hospitals.
• Jan Aushadhi (PMBJP): an alternative supply of cheap generic drugs.
• Uniform Code for Pharmaceutical Marketing Practices (UCPMP): rules on inducements by drug companies.
• Clinical Establishments Act, 2010 / Patients' Rights Charter: regulation of hospitals.
• Out-of-pocket expenditure and PM-JAY: health financing.

16. Common Errors / Trap Areas

• NPPA vs CDSCO: the NPPA regulates prices; the CDSCO regulates drug quality and approval. Do not mix them up.
• Scheduled vs non-scheduled: ceiling prices apply to Schedule-I drugs. Non-scheduled drugs are controlled only through Para 19 or TMR [2][4].
• Year: the TMR on cancer drugs dates to 2019. DPCO dates to 2013, not 1995 (DPCO 1995 was the predecessor Order).
• "42 drugs" vs "526 brands": 42 is the number of drug formulations, 526 the number of brands [2].
• PTR ≠ MRP: the problem is the gap between the two, not the ceiling price itself [1].